Question 1

Why is Novo Nordisk trading at only 10x earnings?

Accepted Answer

The market is pricing in GLP-1 commoditization driven by Eli Lilly competition, India patent revocation enabling generic semaglutide, and compounding pharmacy alternatives. Investors fear that Novo's pricing power will erode significantly over the next 3-5 years, compressing earnings. Whether this fear is proportionate to the actual threat is the central debate.

Question 2

How does the Hims & Hers semaglutide partnership affect Novo Nordisk?

Accepted Answer

The Hims partnership gives Novo branded semaglutide distribution through a direct-to-consumer telehealth platform with over 2 million weight-loss subscribers. This addresses the accessibility criticism that drove patients toward compounded alternatives, potentially recapturing volume that was leaking to the grey market. It expands the addressable market without requiring price cuts on existing channels.

Question 3

What does India's semaglutide patent revocation mean for Novo Nordisk globally?

Accepted Answer

India represents approximately 2% of Novo's global revenue, so the direct financial impact is limited. The precedent risk is more concerning — other markets could challenge patent protections. However, the US, EU, and Japan operate under different patent frameworks, and Wegovy's US composition-of-matter patent extends through 2032. The India decision is a medium-term watch item, not an immediate earnings threat.

Question 4

Is NVO stock a buy at current prices?

Accepted Answer

At $36.64 with a 10.4x P/E, 80.9% gross margins, and 34% net margins, NVO represents deep value in large-cap pharma. The risk-reward skews favorably for investors with a 12-18 month horizon who can tolerate near-term volatility around the May 6 earnings report. A re-rating to even 15x earnings — still below the sector average — implies a price target near $53.

Quarter	Revenue	Net Income	EPS
2025-12-31	$78.43B	$26.65B	$6.06
2025-09-30	$74.98B	$20.01B	$4.50
2025-06-30	$76.86B	$26.50B	$5.96
2025-03-31	$78.09B	$29.03B	$6.54

Novo Nordisk A/S

Price History (1 Year)

AI Analysis

NVO: Three Catalysts, Zero Credit — Still 10x Earnings

Healthcare Peers